CERO — CERO THERAPEUTICS HOLDINGS, INC.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1870404 ·
Last close
$0.01
Market Cap
$787.9K
52W High
$5.66
52W Low
$0.01
ADV30
594,173
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,846,466 | -1,028,830 | 1,899,971 | 937,512 | 32,405,268 |
| Mar 2026 | 0 | — | -4,845,728 | -5,885,914 | 2,205,110 | 857,489 | 11,463,865 |
| Dec 2025 | 0 | — | -4,426,248 | -4,540,621 | 3,641,134 | 1,662,380 | 9,087,596 |
| Sep 2025 | 0 | — | -4,362,579 | -4,856,395 | 3,911,394 | 2,022,072 | 8,454,556 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,395,640
Investing CF
$0
Financing CF
$9,549,592
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-102.83
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-96,724,029
Inventory
—
Receivables
—
ST Investments
$500,000
EBIT TTM
$-19,939,546
Pretax Income TTM
$-20,700,245
Interest Exp TTM
$166,286
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,326,699 | -19,920,262 | 3,641,134 | 9,087,596 | -5,446,462 | -16,080,250 |
| Dec 2024 | — | — | — | 6,206,929 | 8,101,492 | -1,894,563 | — |
| Dec 2023 | 0 | -7,675,049 | -7,289,577 | 5,126,302 | 47,183,997 | -42,057,695 | -5,789,987 |
| Dec 2022 | 0 | -11,971,231 | -11,829,116 | 11,300,000 | 46,200,000 | -34,870,780 | -11,709,311 |
| Dec 2021 | 0 | -11,616,331 | -10,629,620 | — | — | — | -10,094,380 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.26
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGTX | Agentix Corp. | $801.3K | $0.02 | — |
| SCNI | Scinai Immunotherapeutics Ltd. | $1.05M | $1.55 | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $441.8K | $0.06 | — |
| SLXN | Silexion Therapeutics Corp | $1.45M | $0.26 | — |
| CRIS | CURIS INC | $2.01M | $0.83 | — |
News headlines (Yahoo Finance, 1h cache)
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
2026-08-31 11:30 · Yahoo
Delisting of Securities from The Nasdaq Stock Market
2026-07-10 16:00 · Yahoo
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-03-30 12:15 · Yahoo
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
2026-06-15 12:15 · Yahoo
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-04-14 12:15 · Yahoo
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
2026-05-11 12:15 · Yahoo
CERo Therapeutics Provides Shareholder Update
2026-03-11 12:15 · Yahoo
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
2026-02-17 13:00 · Yahoo
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
2026-02-04 14:05 · Yahoo
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplas
2026-01-07 14:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.